TITLE

Insulin degludec in Phase 3 trials

AUTHOR(S)
Elliott, William T.
PUB. DATE
May 2011
SOURCE
Internal Medicine Alert;5/15/2011 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the phase 3 trials of insulin degludec, a ultralong-acting insulin, from Novo Nordisk A/S.
ACCESSION #
62093058

 

Related Articles

  • Pharma: Clinic Roundup.  // BioWorld Today;5/28/2013, Vol. 24 Issue 101, p6 

    The article focuses on the top-line results reported by Novo Nordisk A/S from a Phase IIIa trial testing the potential of GLP-1 drug liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with co-morbidities such as prediabetes, hypertension, and...

  • Successful diabetes drug trial. Investor's Business Daily // Investors Business Daily;2/23/2015, pA02 

    The article reports on the increase in the stocks of pharmaceutical company Novo Nordisk A/S after completing a phase 2 trial for the oral anti-diabetes drug OG217SC.

  • NovoLog (insulin aspart [rDNA origin] injection) Novo Nordisk.  // Clinician Reviews;Mar2007, Vol. 17 Issue 3, p52 

    The article evaluates the Novolog® insulin aspart injection from Novo Nordisk.

  • Novo says no to Lilly's insulin.  // Drug Topics;8/19/96, Vol. 140 Issue 16, p8 

    Details a letter issued by Novo Nordisk Pharmaceuticals to pharmacists recommending against the use of Eli Lilly manufactured Humulin insulin cartridges with NovoPen 1.5. Approval by Food & Drug Administration on use of NovoPen 1.5 with Novolin PenFill insulin cartridges.

  • Novo Nordisk Data Show That Ultra-Long-Acting Insulin Degludec Can Be Flexibly Dosed at Any Time of the Day at a Different Time from Day to Day in People with Type 2 Diabetes.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p1110 

    The article reports on the findings of a clinical study by Denmark-based Novo Nordisk A/S that show that its investigational ultra-long-acting insulin degludec can reduce blood sugar in patients with type 2 diabetes. It indicates that the insulin degludec can be administered anytime from day to...

  • NEW PRODUCTS.  // Monthly Prescribing Reference;Jan2016, Vol. 32 Issue 1, pA13 

    The article offers information about the humanized interleukin-5 antagonist monoclonal antibody Nucala and the insulin analog Tresiba from pharmaceutical companies GlaxoSmithKline and Novo Nordisk A/S, respectively. Topics include the medical conditions that the products are indicated for, the...

  • Lilly suffers another bruise from Novo.  // Indianapolis Business Journal;3/14/2011, Vol. 32 Issue 2, p13A 

    The article reports on Novo Nordisk A/S scoring a victory against its rival Eli Lilly and Co. in the diabetes business and maintained its global insulin market share in the U.S.

  • Your Complete Insulin Reference Guide From Diabetes Health.  // Diabetes Health;Jun2004, Vol. 13 Issue 6, p56 

    Presents a complete insulin reference guide for people with diabetes. Humalog Vial from Lilly; NovoLog PenFill from Novo Nordisk; Lantus Vial from Aventis.

  • NNE injects insulin capacity. Whitfield, Mark // European Chemical News;8/4/2003, Vol. 79 Issue 2064, p29 

    Reports on the completion of a production plant for the manufacture and purification of insulin by Novo Nordisk Engineering (NNE) at Kalundborg in Copenhagen, Denmark in 2003. Areas of production; Importance of extra manufacturing capacity; Statement issued by Ole Regnar Hansen, project...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics